Vertex snags FDA nod for once-daily cystic fibrosis triplet Alyftrek as switch from Trikafta kicks off
As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has chalked up a win in its specialty area of cystic fibrosis. | The FDA has approved Vertex’s Alyftrek,
Vertex Wins FDA Approval for New Cystic Fibrosis Option but Stock Still Down
The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion in 2023. It’s welcome good news for Vertex following last week’s subpar clinical results for its non-opioid analgesic.
Vertex drug for cystic fibrosis wins approval
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello! This is our last
Vertex' Trikafta Gets Expanded FDA Approval For Cystic Fibrosis Treatment
Vertex Pharmaceuticals (VRTX) said Friday the U.S. Food and Drug Administration expanded its approval of a cystic fibrosis treatment,
Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek
The drug is also eligible for use in CF patients who have discontinued Trikafta or Vertex’s other CF medicines. Similar regulatory filings are also under review in Europe. However, the drug’s ...
Vertex secures two FDA wins for cystic fibrosis, both with boxed warnings
Vertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.
Vertex wins approval for new once-daily CF drug
Vertex Pharmaceuticals Inc. notched two FDA victories late Friday for its cystic fibrosis medicines, increasing the number of ...
Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?
Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% ...
STAT9d
Viridian confirms benefit of drug for thyroid eye disease
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
How hockey became a lifeline for Gunnar and Boomer Esiason
Throughout Gunnar Esiason's journey with cystic fibrosis, the sport of hockey has always been huge part of his family. See their story on E60 (7 p.m. ET, ESPN).
A clinical guide for a special kind of diabetes
Cystic fibrosis, a genetic disease that attacks the lungs, affects roughly 1 in 3,000 people, and cystic fibrosis-related ...
Vertex Pharmaceuticals price target raised to $430 from $426 at Scotiabank
Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $430 from $426 and keeps a Sector Perform rating on the shares.